**Advanced Prostate**

**Castrate Resistant**

- **Hormone Naive**
  - Non-Metastatic
  - Metastatic

- **Non-Metastatic**
  - IRB # 11268: Salvage radiation + enzalutamide/placebo for recurrent prostate cancer
  - IRB # 19633: SWOG 1802: SST +/- definitive tx for metastatic disease
  - IRB # 17717: Degarelix, apalutamide, abiraterone acetate in biochemically relapsed prostate cancer

- **Metastatic**
  - 1st Line: No prior AR targeting Agent
    - New Trial Coming Soon
  - 2nd Line: Post-AR targeting Agent
    - IRB # 16294: Phase I Safety and Tolerability of ZEN003694 w/ enzalutamide or abiraterone acetate
    - IRB # 18231: Phase 1/2a Study of CORT125281 and enzalutamide
    - IRB # 16962: Phase 3 Study of pembrolizumab/placebo plus docetaxel with prednisone (KN-921)

- **Chemotherapy Naive**
  - IRB # 17864: Phase III Study of Rucaparib versus physician’s choice for patients with mCRPC associated with Homologous Recombination Deficiency
  - IRB # 18231: Phase 1/2a Study of CORT125281 and enzalutamide

- **Post Taxane-based Chemotherapy**
  - IRB # 19002: Lu-PSMA radionuclide in PSMA-Positive mCRPC

- **Supportive Care/Biomarker**
  - IRB # 15944: Falls in Elderly Men Taking Enzalutamide

**Supportive care**

**CROSS-DISEASE TRIALS:**

- New Trial Coming Soon
- IRB # 18084: S1609 DART – Rare Tumors

**Key**

- Open for Enrollment
- In Development
- Enrollment on Hold

**http://www.ohsu.edu/research/rda/so/knight.php**

8/28/2019